{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:39:36Z","timestamp":1792611576598,"version":"4.5.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>\n                    Ibrexafungerp (SCY-078) is a novel first-in-class antifungal agent targeting glucan synthase.\n                    <jats:named-content content-type=\"genus-species\">Candida auris<\/jats:named-content>\n                    is an emerging multidrug-resistant species that has caused outbreaks on five continents. We investigated the\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity of ibrexafungerp against\n                    <jats:named-content content-type=\"genus-species\">C. auris<\/jats:named-content>\n                    by applying EUCAST E.Def 7.3.1 methodology.\n                    <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>\n                    , as well as anidulafungin, micafungin, amphotericin B, fluconazole, voriconazole, and isavuconazole, were included as comparators.\n                  <\/jats:p>","DOI":"10.1128\/aac.02136-19","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T10:08:21Z","timestamp":1576058901000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":67,"title":["<i>In Vitro<\/i>\n                    Activity of Ibrexafungerp (SCY-078) against\n                    <i>Candida auris<\/i>\n                    Isolates as Determined by EUCAST Methodology and Comparison with Activity against\n                    <i>C. albicans<\/i>\n                    and\n                    <i>C. glabrata<\/i>\n                    and with the Activities of Six Comparator Agents"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":false,"given":"Maiken Cavling","family":"Arendrup","sequence":"first","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Meinike","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-023X","authenticated-orcid":false,"given":"Rasmus Kr\u00f8ger","family":"Hare","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-7462","authenticated-orcid":false,"given":"Anuradha","family":"Chowdhary","sequence":"additional","affiliation":[{"name":"Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00435-17"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-17"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx422"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007638"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1164-y"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.13.18-00136"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006290"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-018-0342-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy411"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01225-18"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02319-17"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02233-18"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx010"},{"key":"e_1_3_2_18_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2010. Amphotericin B: rationale for the clinical breakpoints version 1.0. EUCAST Stockholm Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/AmphotericinB_rationale_20110429.pdf."},{"key":"e_1_3_2_19_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Rationale documents for antifungal agents. EUCAST Stockholm Sweden. http:\/\/www.eucast.org\/astoffungi\/rationale_documents_for_antifungals\/."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-17"},{"key":"e_1_3_2_21_2","unstructured":"Barat S Borroto-Esoda K Angulo D. 2018. Ibrexafungerp (formerly SCY-078) displays potent in vitro activity against C. glabrata isolates with mutations in fks genes. ESCMID\/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance Lisbon Portugal."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz262"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.017"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-17"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02136-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02136-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:44:55Z","timestamp":1645461895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02136-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.02136-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02136-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02136-19"}}